Cargando…
Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis
The additive effects of ezetimibe, evolocumab or alirocumab on lipid level, plaque volume, and plaque composition using intravascular ultrasound (IVUS) remain unclear. METHODS: According to the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement, we performed a systematic re...
Autores principales: | Liang, Di, Li, Chang, Tu, Yanming, Li, Zhiyong, Zhang, Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575789/ https://www.ncbi.nlm.nih.gov/pubmed/36254013 http://dx.doi.org/10.1097/MD.0000000000031199 |
Ejemplares similares
-
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022) -
Immunoadsorption treatment for dilated cardiomyopathy: A PRISMA-compliant systematic review and meta-analysis
por: Bian, Ru-tao, et al.
Publicado: (2021) -
The safety and effectiveness of salvianolate in preventing perioperative venous thromboembolism in China: A PRISMA-compliant meta-analysis based on RCTs
por: Chai, Yu-na, et al.
Publicado: (2021) -
Association of smoking with postoperative atrial fibrillation in patients with cardiac surgery: A PRISMA-compliant article
por: Wan, Qin, et al.
Publicado: (2021) -
Association of β-fibrinogen polymorphisms and venous thromboembolism risk: A PRISMA-compliant meta-analysis
por: Li, Da, et al.
Publicado: (2019)